The interaction between RBBP6 and ERRα opens new therapeutic avenues, suggesting that modulating RBBP6‐ERRα interactions could be a strategy for preserving mitochondrial function and slowing DKD progression. Here, RBBP6 is linked to diabetic kidney disease.